
Conference Coverage
about 8 hours ago
Best Practices to Re-Engage Lost Hep B Patients: Helen Nde, MPHabout 21 hours ago
Untreated MASH With T2D to Drive Costs 5-Fold: Zobair Younossi, MDabout 22 hours ago
Bring on the Breakthroughs: ASCO Takes Translation to More Patientsabout 23 hours ago
Pevifoscorvir Shows Strong HBV Activity, Durable Antigen Suppressionabout 23 hours ago
MASH Care Demands More Than New Drugs: Meena Bansal, MDLatest Content

FDA Approves Durvalumab Plus BCG as First Immunotherapy Combo Regimen for High-Risk NMIBC

AJMC® in the Press, May 29, 2026

AI Cannot Fix a Broken Claims Paradigm

Leveraging Health Plan Infrastructure, Patient Voices to Improve Food Insecurity Identification: Jonathan Wrathall, PhD

Review Findings Question the Assumed Skin Cancer Risks in Alopecia Areata

Shorts










Podcasts
Center on Health Equity & Access
All News

Mezigdomide, a powerful CELMoD, doubles PFS in relapsed multiple myeloma, offering hope when IMiDs stop working.

Elliot Tapper, MD, explains how digital health, precise screening, and direct hepatology care can treat alcohol-associated liver disease and mental health.

Study finds endometriosis severity plateaus after 30, but surgery risk and complexity climb in older women as fibrosis and adhesions build.

Phenotype-based care improves childhood obesity diagnosis and treatment, including obesity types, hypothalamic obesity, drugs, and surgery.

A population study finds familial melanoma gene variants are more common than thought, linking them to a higher risk of multiple cancers beyond melanoma.

A survey of health care and life sciences executives found that the top challenges in the sectors included policy uncertainty and declining reimbursement rates.

The scoping review shows menopause and multiple sclerosis (MS) shift from fewer relapses to higher symptom burden, highlighting care gaps for older women with MS.

ASCO 2026 spotlights practice-changing cancer data: PROTEUS in prostate cancer, RAS(ON) inhibitor daraxonrasib, new bispecifics, and GLP-1 signals.

New data highlight pevifoscorvir’s potent antiviral activity and sustained hepatitis B antigen suppression lasting up to 96 weeks after treatment.

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes data remain critical gaps.























